332 related articles for article (PubMed ID: 34742355)
1. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm.
Silver JA; Bogatchenko M; Pusztaszeri M; Forest VI; Hier MP; Yang JW; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Nov; 50(1):63. PubMed ID: 34742355
[TBL] [Abstract][Full Text] [Related]
2. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
5. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between Ultrasound-guided Fine-needle Aspiration Combined with BRAF
Zhang Y; Luo YK; Zhang Y; Zhang MB; Guang Y; Xie F; Jiang B; Tang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Aug; 41(4):517-523. PubMed ID: 31484615
[TBL] [Abstract][Full Text] [Related]
7. Younger Than 55 Years Old and
Lai Y; Gu Y; Yu M; Deng J
Int J Gen Med; 2023; 16():1403-1414. PubMed ID: 37155469
[TBL] [Abstract][Full Text] [Related]
8. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
Zheng X; Wei S; Han Y; Li Y; Yu Y; Yun X; Ren X; Gao M
Ann Surg Oncol; 2013 Jul; 20(7):2266-73. PubMed ID: 23370668
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma.
Dong Y; Wang D; Luo Y; Chen L; Bai H; Shen Y; Zhang Y; Chen X; Su X; Zhao J; Liu H; Lu J; Yao Z; Zhao Y; He C; Li X
Oncol Lett; 2021 Mar; 21(3):188. PubMed ID: 33574927
[TBL] [Abstract][Full Text] [Related]
10. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
11. Association of BRAF
Attia AS; Hussein M; Issa PP; Elnahla A; Farhoud A; Magazine BM; Youssef MR; Aboueisha M; Shama M; Toraih E; Kandil E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555268
[TBL] [Abstract][Full Text] [Related]
12. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
13. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma.
Kim KJ; Kim SG; Tan J; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
Eur J Cancer; 2020 Jan; 124():161-169. PubMed ID: 31790974
[TBL] [Abstract][Full Text] [Related]
14. Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer.
Semsar-Kazerooni K; Morand GB; Payne AE; da Silva SD; Forest VI; Hier MP; Pusztaszeri MP; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2022 Mar; 51(1):9. PubMed ID: 35246262
[TBL] [Abstract][Full Text] [Related]
15. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
16. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
17. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
Liu Z; Lv T; Xie C; Di Z
Am J Med Sci; 2018 Aug; 356(2):130-134. PubMed ID: 30219154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
